Home » Newsletters » BioWorld Science

BioWorld Science

March 8, 2012

View Archived Issues

Novel kinase inhibitors patented

Fatty acid blocks HIV-1 infection in ex vivo cervical tissue model

HCV NS3 resistance variants detected after 7-day MK-5172 course

Strategic alliance aims to develop and commercialize new vaccines

Telormedix receives funding to develop Toll-like receptor 7 modulators

Abbott reports novel inhibitors of GlyT1

New sodium/glucose cotransporter 2 inhibitors developed in China

Roche discovers new HSL inhibitors

Scientists in Brazil identify new phosphodiesterase 5 inhibitors

Novel tablet for type 2 diabetes available in U.S. pharmacies

Horizon Pharma and Mundipharma amend commercialization agreement

Plant-derived lactic acid bacteria may help combat obesity

New anti-infectives designed at Merck & Co.

French company presents novel inhibitors of TNF-alpha

Antigen-specific MS therapy in phase I development

Mersana partners to develop novel antibody-drug conjugates

Courtagen and Avaxia join forces to create new assay

Sosei commences Japanese phase I study of antifungal

Exonhit receives E.U. grant for consortium work on predictive biomarkers

NME improves cognition in schizophrenia model

Alexza and Ferrer amend commercial partnership for Adasuve

ReGenx and Asklepios establish agreement for hemophilia A

Feraheme shows noninferiority to intravenous iron sucrose in iron deficiency anemia

KBP BioSciences reports new mineralocorticoid receptor antagonists

New diacylglycerol O-acyltransferase 1 inhibitors reported by Merck & Co.

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...